OncoSil Seeks ASX Quotation for New Tranche of Deferred Options

OncoSil Medical Ltd ( (AU:OSL) ) has shared an update.

OncoSil Medical Ltd has lodged an application with the ASX for quotation of 306,678 deferred options, designated as OSLOE and expiring on June 30, 2027, with an issue date of March 17, 2026. The options are being quoted as securities issued under a previously announced transaction, indicating a continuation of the company’s established capital management and financing strategy within the public markets.

This move modestly expands the company’s quoted securities base and may provide additional leverage for future funding or incentive structures. For investors and other stakeholders, the quotation of these options clarifies the tradable instruments on issue and underscores OncoSil’s ongoing engagement with equity-based mechanisms to support its operational and strategic objectives.

The most recent analyst rating on (AU:OSL) stock is a Hold with a A$0.55 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.

More about OncoSil Medical Ltd

OncoSil Medical Ltd is an ASX-listed medical technology company focused on cancer treatment solutions. The company develops and commercialises oncological devices and therapies, with its securities traded under the ticker OSL on the Australian Securities Exchange, reflecting its positioning in the healthcare and biotech investment market.

Average Trading Volume: 61,650

Technical Sentiment Signal: Sell

Current Market Cap: A$13.22M

For detailed information about OSL stock, go to TipRanks’ Stock Analysis page.